Are flea-fighting pills gaining ground on OTC topicals?

PetMed Express ($PETS) CEO Menderes Akdag raised a few eyebrows on October 20 when he blamed his company's missed quarterly profit and sales targets on the weather. Specifically, he said in a conference call with investors, last winter's frigid temperatures shortened flea-and-tick season, which dampened demand for topical remedies. But an analyst interviewed by MarketWatch suspects the real culprit is that over-the-counter flea-and-tick fighters are losing ground to new pills like Nexgard, made by Frontline Vet Labs, and Merck ($MRK) Animal Health's Bravecto. PetMed's stock dropped 4% after it announced the missed quarterly results last Monday. Article

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal…